SARS-CoV-2 Variants and Vaccines.
Philip R Krause 
;
Thomas R Fleming;
Ira M Longini;
Richard Peto;
Sylvie Briand;
David L Heymann;
Valerie Beral;
Matthew D Snape;
Helen Rees;
Alba-Maria Ropero;
+11 more...
Ran D Balicer;
Jakob P Cramer;
César Muñoz-Fontela;
Marion Gruber;
Rogerio Gaspar;
Jerome A Singh;
Kanta Subbarao;
Maria D Van Kerkhove;
Soumya Swaminathan;
Michael J Ryan;
Ana-Maria Henao-Restrepo;
(2021)
SARS-CoV-2 Variants and Vaccines.
New England Journal of Medicine, 385 (2).
pp. 179-186.
ISSN 0028-4793
DOI: 10.1056/NEJMsr2105280
;
Thomas R Fleming;
Ira M Longini;
Richard Peto;
Sylvie Briand;
David L Heymann;
Valerie Beral;
Matthew D Snape;
Helen Rees;
Alba-Maria Ropero;
+11 more...
Ran D Balicer;
Jakob P Cramer;
César Muñoz-Fontela;
Marion Gruber;
Rogerio Gaspar;
Jerome A Singh;
Kanta Subbarao;
Maria D Van Kerkhove;
Soumya Swaminathan;
Michael J Ryan;
Ana-Maria Henao-Restrepo;
(2021)
SARS-CoV-2 Variants and Vaccines.
New England Journal of Medicine, 385 (2).
pp. 179-186.
ISSN 0028-4793
DOI: 10.1056/NEJMsr2105280
Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19). Moreover, if some variants of concern have increased transmissibility or virulence, the importance of efficient public health measures and vaccination programs will increase. The global response must be both timely and science based.
-
picture_as_pdf - Krause-etal-2021-SARS-CoV-2-Variants-and-Vaccines.pdf
-
subject - Published Version
-
copyright - Available under Copyright the publishers
Downloads